🔎 Trials Near Me

Home › Kanser sa Prostate › Mississippi

Pag-aaral pangklinika para sa Kanser sa Prostate sa Mississippi

7 pag-aaral para sa Kanser sa Prostate ang naghahanap ng mga kalahok sa mga site sa Mississippi.

Mga Lungsod sa Mississippi

Opisyal na teksto ng pag-aaral (English)

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • University of Mississippi Medical Center, Jackson
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT03866382

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • Baptist Cancer Center-Grenada, Grenada
  • Baptist Memorial Hospital and Cancer Center-Union County, New Albany
  • Baptist Memorial Hospital and Cancer Center-Oxford, Oxford
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Ago 19, 2026 · NCT04423211

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  • University of Mississippi Medical Center, Jackson
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Hul 14, 2026 · NCT06592924

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

  • University of Mississippi Med Ctr, Jackson
Nagre-recruitPhase 4
Edad 18 hanggang 100 · Kalalakihan · Na-update Hun 4, 2026 · NCT05803941

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

  • University of Mississippi Medical Center, Jackson
Nagre-recruitObservasyonal na pag-aaral
Edad 21 pataas · Kalalakihan · Na-update May 22, 2026 · NCT03151629

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Hattiesburg
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.